Recent studies demonstrated high potency of combining novel Erk1/2i (LY3214996) and CDK4/6i (LY2835219) in solid tumors and acute myeloid leukemia, and clinical trials evaluating Erk1/2i + CDK4/6i therapy are ongoing in advanced cancers [20, 24–27]. The gene discussed is CDK4; the disease is cancer.